KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Clover Health Investments (CLOV) EBITDA Margin (2020 - 2025)

Clover Health Investments (CLOV) has disclosed EBITDA Margin for 6 consecutive years, with 9.15% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 1632.0% year-over-year to 9.15%, compared with a TTM value of 0.39% through Dec 2025, up 347.0%, and an annual FY2025 reading of 17.09%, up 2017.0% over the prior year.
  • EBITDA Margin was 9.15% for Q4 2025 at Clover Health Investments, up from 4.85% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 9.15% in Q4 2025 and bottomed at 727.54% in Q4 2023.
  • Average EBITDA Margin over 5 years is 48.77%, with a median of 7.72% recorded in 2024.
  • The sharpest move saw EBITDA Margin crashed -71826bps in 2023, then surged 72037bps in 2024.
  • Year by year, EBITDA Margin stood at 28.76% in 2021, then surged by 68bps to 9.28% in 2022, then tumbled by -7742bps to 727.54% in 2023, then soared by 99bps to 7.17% in 2024, then skyrocketed by 228bps to 9.15% in 2025.
  • Business Quant data shows EBITDA Margin for CLOV at 9.15% in Q4 2025, 4.85% in Q3 2025, and 2.14% in Q2 2025.